Upper urinary tract disease: what we know today and unmet needs

Détails

Ressource 1Télécharger: BIB_C09105C57C8D.P001.pdf (271.27 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_C09105C57C8D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Upper urinary tract disease: what we know today and unmet needs
Périodique
Translational Andrology and Urology
Auteur⸱e⸱s
Mathieu , Bensalah , Lucca , Mbeutcha , Rouprêt , Shariat 
ISSN
2223-4691 (Electronic)
ISSN-L
2223-4683
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
4
Numéro
3
Pages
261-272
Langue
anglais
Notes
Publication types: Review Article ; review-article Identifiant PubMed Central: PMC4708228
Résumé
PURPOSE: Upper tract urothelial carcinoma (UTUC) is a rare and poorly investigated disease. Intense collaborative efforts have increased our knowledge and improved the management of the disease. The objective of this review was to discuss recent advances and unmet needs in UTUC.
METHODS: A non-systematic Medline/PubMed literature search was performed on UTUC using the terms "upper tract urothelial carcinoma" with different combinations of keywords. Original articles, reviews and editorials in English language were selected based on their clinical relevance.
RESULTS: UTUC is a disease with specific epidemiologic and risk factors different to urothelial carcinoma of the bladder (UCB). Similarly to UCB, smoking increases the risk of UTUC and worsens its prognosis, whereas aristolochic acid (AA) exposure and mismatch repair genes abnormality are UTUC specific risk factors. A growing understanding of biological pathways involved in the tumorigenesis of UTUC has led to the identification of promising prognostic/predictive biomarkers. Risk stratification of UTUC is difficult due to limitations in staging and grading. Modern imaging and endoscopy have improved clinical decision-making, and allowed kidney-sparing management and surveillance in favorable-risk tumors. In high-risk tumors, radical nephroureterectomy (RNU) remains the standard. Complete removal of the intramural ureter is necessary with inferiority of endoscopic management. Post-RNU intravesical instillation has been shown to decrease bladder cancer recurrence rates. While the role of neoadjuvant cisplatin based combination chemotherapy and lymphadenectomy are not clearly established, the body of evidence suggests a survival benefit to these. There is currently no evidence for adjuvant chemotherapy (AC) in UTUC.
CONCLUSIONS: Despite growing interest and understanding of UTUC, its management remains challenging, requiring further high quality multicenter collaborations. Accurate risk estimation is necessary to avoid unnecessary RNUs while advances in technology are still required for optimal kidney-sparing approaches.
Mots-clé
Upper tract urothelial carcinoma (UTUC), risk factors, predictive tools, ureteroscopy, radical nephroureterectomy (RNU), chemotherapy
Pubmed
Création de la notice
11/10/2016 15:30
Dernière modification de la notice
20/08/2019 15:35
Données d'usage